247 related articles for article (PubMed ID: 30894032)
21. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
Chang HY; Chen KC; Fong MC; Feng AN; Fu HN; Huang KC; Chong E; Yin WH
J Cardiol; 2020 Mar; 75(3):233-241. PubMed ID: 31563433
[TBL] [Abstract][Full Text] [Related]
22. PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
Mentz RJ; Xu H; O'Brien EC; Thomas L; Alexy T; Gupta B; Vilaro J; Lala A; DeVore AD; Dhingra R; Briasoulis A; Simon MA; Stehlik J; Rodgers JE; Dunlay SM; Abshire M; Wells QS; Barringhaus KG; Eckman PM; Lowes BD; Espinoza J; Blanco R; Shen X; Duffy CI; Hernandez AF
Am Heart J; 2020 Dec; 230():35-43. PubMed ID: 32980364
[TBL] [Abstract][Full Text] [Related]
23. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
Omar AMS; Murphy S; Felker GM; Piña I; Butler J; Liu Y; Mohebi R; Bhatia K; Ward JH; Williamson KM; Solomon SD; Januzzi JL; Contreras J
J Card Fail; 2024 May; 30(5):653-665. PubMed ID: 37816446
[TBL] [Abstract][Full Text] [Related]
24. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
Ibrahim NE; Piña IL; Camacho A; Bapat D; Felker GM; Maisel AS; Butler J; Prescott MF; Abbas CA; Solomon SD; Januzzi JL;
Circ Heart Fail; 2020 Nov; 13(11):e007829. PubMed ID: 33016100
[TBL] [Abstract][Full Text] [Related]
25. Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
Guerra F; Ammendola E; Ziacchi M; Aspromonte V; Pellegrino PL; Del Giorno G; Dell'Era G; Pimpini L; Santoro F; Floris R; Stronati G; Nigro G; Paolisso P; Guido A; Maglia G; Brunetti ND; Carbone A; Gravellone M; Antonicelli R; Cannone M; Accogli M; Dello Russo A; Palmisano P
Eur J Clin Pharmacol; 2021 Dec; 77(12):1835-1842. PubMed ID: 34279677
[TBL] [Abstract][Full Text] [Related]
26. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
27. Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series.
Severini D; Mboumi K
Curr Med Res Opin; 2019 May; 35(sup3):7-11. PubMed ID: 30894026
[TBL] [Abstract][Full Text] [Related]
28. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
Khan MS; Felker GM; Piña IL; Camacho A; Bapat D; Ibrahim NE; Maisel AS; Prescott MF; Ward JH; Solomon SD; Januzzi JL; Butler J
JACC Heart Fail; 2021 Feb; 9(2):137-145. PubMed ID: 33309581
[TBL] [Abstract][Full Text] [Related]
29. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
[TBL] [Abstract][Full Text] [Related]
30. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
[TBL] [Abstract][Full Text] [Related]
31. Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
Camilli M; Iannaccone G; Russo M; Meucci MC; Chiorazzo G; Natali R; Mango F; Bonanni A; Montone RA; Graziani F; Locorotondo G; Massetti M; Lanza GA; Aspromonte N; Crea F; Lombardo A
Int J Cardiol; 2023 Sep; 387():131110. PubMed ID: 37290664
[TBL] [Abstract][Full Text] [Related]
32. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
[TBL] [Abstract][Full Text] [Related]
33. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
[TBL] [Abstract][Full Text] [Related]
34. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
35. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
[TBL] [Abstract][Full Text] [Related]
36. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
[TBL] [Abstract][Full Text] [Related]
37. Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.
Moon MG; Hwang IC; Lee HJ; Kim SH; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ; Cho GY
JACC Cardiovasc Imaging; 2022 Sep; 15(9):1525-1541. PubMed ID: 36075612
[TBL] [Abstract][Full Text] [Related]
38. Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan.
Lin PL; Lee YH; Liu LY; Tsai CT; Yang TF; Chiou WR; Hsieh MY; Chang HY; Huang CC
J Cardiovasc Pharmacol Ther; 2022; 27():10742484221107799. PubMed ID: 35713466
[TBL] [Abstract][Full Text] [Related]
39. Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
Holm N; Bromage DI; Cannata A; DeCourcey J; Bhatti P; Huang M; McDonagh TA
J Cardiovasc Med (Hagerstown); 2022 Jan; 23(1):37-41. PubMed ID: 34632983
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
Pogge EK; Davis LE
Am J Cardiovasc Drugs; 2018 Apr; 18(2):143-151. PubMed ID: 29455335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
